loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Vijaya Diagnostic Centre Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Vijaya Diagnostic Centre Ltd. 04 Nov 2025 15:20 PM
Result PDF

Q2FY26 Quarterly Result Announced for Vijaya Diagnostic Centre Ltd.

Healthcare Services company Vijaya Diagnostic Centre announced Q2FY26 results

  • Revenue from Operations: Rs 2,015.6 million compared to Rs 1,829.5 million during Q2FY25, change 10.2%.
  • EBITDA: Rs 818.3 million compared to Rs 759.8 million during Q2FY25, change 7.7%.
  • EBITDA Margin: 40.6% for Q2FY26.
  • PAT: Rs 432.8 million compared to Rs 421.2 million during Q2FY25, change 2.7%.
  • PAT Margin: 21.5% for Q2FY26.

Suprita Reddy, MD & CEO, said: “Vijaya reported steady revenue growth for the Q2FY26 and H1FY26, achieving a YoY growth of 10.2% and 14.9% respectively, largely driven by volume growth.

I am happy to announce successful launch of our hub centre in Kasba, Kolkata during the quarter - marking our 3rd hub centre launch in West Bengal this year. 2 more hubs in West Bengal are on track to be commissioned in Q3FY26.

We also received the NCLT order in October for the merger of Medinova Diagnostic Services Limited with the Company w.e.f. 1st April 2024.

I am pleased to share that our Yelahanka hub centre in Bengaluru has achieved break-even within just two quarters of commencing operations - well ahead of the projected timeline of 1 year. This performance highlights the strong demand for quality integrated diagnostics in the region.

Building on this positive momentum, we have finalised the lease for our flagship centre at Bannerghatta, Bengaluru. This facility will be equipped with an automated lab and advanced radiology equipment including PET-CT with an advanced CT. As we speak, we are actively exploring few more locations in Bengaluru for our hub expansion, along with select locations in West Bengal and our core geographies for spoke additions.”

Result PDF

Result PDF

Healthcare Services company Vijaya Diagnostic Centre announced Q1FY26 results

  • Revenue from Operations: Rs 1,880.5 million, up 20.4% YoY from Rs 1,562.2 million
  • EBITDA: Rs 735.3 million, a 20.1% YoY increase from Rs 612.4 million
  • EBITDA Margin: 39.1%, down 10 bps from 39.2%
  • Profit After Tax (PAT): Rs 383.4 million, up 3.5% YoY from Rs 313.5 million
  • PAT Margin: 20.4%, up 32 bps from 20.1%

Commenting on the Business Outlook, Suprita Reddy, MD & CEO said “Vijaya reported another strong financial quarter, achieving a YOY growth of 20.4%, with our Hyderabad market’s contribution returning to double-digit growth this quarter. The strong performance was largely driven by volume and change in the test mix.

I'm happy to state that all the new hubs in Pune, Bengaluru, and West Bengal are up and running, with steady footfall. We remain optimistic about achieving break-even across all centres within the 12 months with 1 hub centre in Bengaluru on track to reach break-even earlier than the estimated timeline.

I’m also pleased to share that our Nizamabad hub centre has achieved break-even within 2 quarters of its full-fledged operations. Looking ahead, we would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal. The other 2 hubs in West Bengal are also on track to be operationalized in 2nd half of FY26.”

Result PDF

Healthcare Services company Vijaya Diagnostic Centre announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from Operations: Rs 1,732.4 million vs Rs 1,552.1 million during Q4FY24 (YoY change: 11.6%)
  • EBITDA: Rs 688.6 million vs Rs 631.1 million during Q4FY24 (YoY change: 9.1%)
  • EBITDA Margin: 39.8% vs 40.7% during Q4FY24 (change: -91 bps)
  • Profit After Tax (PAT): Rs 346.4 million vs Rs 334.5 million during Q4FY24 (YoY change: 3.5%)
  • PAT Margin: 20.0% vs 21.6% during Q4FY24 (change: -156 bps)

FY25 Financial Highlights:

  • Revenue from Operations: Rs 6,813.9 million vs Rs 5,478.1 million during Q4FY24 (YoY change: 24.4%)
  • EBITDA: Rs 2,732.2 million vs Rs 2,209.0 million during Q4FY24 (YoY change: 23.7%)
  • EBITDA Margin: 40.1% vs 40.3% during Q4FY24 (change: -23 bps)
  • Profit After Tax (PAT): Rs 1,430.8 million vs Rs 1,188.3 million during Q4FY24 (YoY change: 20.4%)
  • PAT Margin: 21.0% vs 21.7% during Q4FY24 (change: -69 bps)

Suprita Reddy, MD & CEO, said: “Vijaya reported another strong financial year with YoY growth of 24.4% and an organic growth of 18.9%. I’m happy to announce the successful launch of 6 hubs in the last 2 months - 2 each in Pune, West Bengal and Bengaluru. Additionally, the execution of 3 more hubs in West Bengal is progressing as planned and is expected to be commercialized within the next 3 to 4 months. We have also finalized leases for two hubs in Tier-2 locations of AP & Telangana, which are scheduled to become operational in H2FY26.

After a strong performance in FY25, we had a promising start to the new financial year, with a notable increase in both footfalls and revenue across our network.

Moving forward, our key areas of focus would be stabilisation of the newly launched hubs and building strong brand equities in these new geographies, commissioning additional new hubs in West Bengal and Core geographies, investment in technology and strengthening our talent pool across critical departments.”

Result PDF

Healthcare Services company Vijaya Diagnostic Centre announced Q3FY25 results

  • Revenue from Operations: Rs 1,689.8 million compared to Rs 1,326.9 million during Q3FY24, change 27.3%.
  • EBITDA: Rs 671.3 million compared to Rs 523.1 million during Q3FY24, change 28.3%.
  • EBITDA margin: 39.7% for Q3FY25.
  • PAT: Rs 351.6 million compared to Rs 258.5 million during Q3FY24, change 36.0%.
  • PAT margin: 20.8% for Q3FY25.

Suprita Reddy, MD & CEO said: “I’m pleased to announce another strong quarter, marked by a remarkable year-on-year revenue growth of 27.3%, with a solid 20.2% growth achieved organically. This strong performance was primarily driven by volume across both Pathology and Radiology segments.

I am happy to share that we have operationalized our 1st centre at Pimple Saudagar, Pune (Spoke) under Vijaya PH Brand in this month, following the PH acquisition.

Looking ahead, I am excited to announce that we would be commissioning 6 hubs across Pune, West Bengal and Bengaluru in the coming 3 months, taking our total hub addition to 9 in the 12-month period which marks a significant milestone in the history of Vijaya.

We have also made key strategic hires at the mid and senior levels across functions to support the management in driving the next phase of growth.”

Result PDF

Healthcare Services company Vijaya Diagnostic Centre announced Q2FY25 results

  • Revenue from Operations: Rs 1,829.5 million compared to Rs 1,388.6 million during Q2FY24, change 31.8%.
  • EBITDA: Rs 759.8 million compared to Rs 573.7 million during Q2FY24, change 32.5%.
  • EBITDA Margin: 41.5% for Q2FY25.
  • PAT: Rs 419.4 million compared to Rs 333.2 million during Q2FY24, change 26.9%.
  • PAT margin: 22.9% for Q2FY25.

Suprita Reddy, MD & CEO said: “I’m excited to announce another key milestone in our growth journey. We have delivered a robust quarter, achieving an impressive 31.8% YoY revenue growth, of which 23.0% was organic. This strong performance was driven primarily by volume, with contributions coming from both our existing and newly launched centres.

I’m also delighted to share that we successfully launched operations at our Hub center in Ongole this August, and the response in the first two months has been very promising. In addition, we are excited to begin operations at our new state-of-the-art facility in Nizamabad tomorrow. This center features cuttingedge technologies, including a 3T MRI, CT scan, an automated lab, and a range of basic radiology modalities.

We’ve also upgraded our spoke centre in Gurgaon, transforming it into a fully equipped hub with the addition of MRI and CT machines. This enhancement enables us to provide a complete range of services, from basic blood tests to advanced imaging, all conveniently available under one roof at our Gurgaon centre.”

Result PDF

Healthcare Services company Vijaya Diagnostic Centre announced Q1FY25 results:

  • Revenue from Operations: Rs 1,562.2 million, showing a 29.1% increase YoY from Rs 1,210.5 million in Q1FY24 and a 0.7% increase QoQ from Rs 1,552.1 million in Q4FY24.
  • Revenue from Operations (excluding PH): Rs 1,448.1 million, a 19.6% YoY increase from Rs 1,210.5 million in Q1FY24 and a 1.0% QoQ increase from Rs 1,434.3 million in Q4FY24.
  • EBITDA: Rs 612.4 million, representing a 27.3% YoY increase from Rs 481.2 million in Q1FY24 but a 3.0% decrease QoQ from Rs 631.1 million in Q4FY24.
  • EBITDA Margin: 39.2%, which is a decrease of 60 basis points YoY from 39.8% in Q1FY24 and a decrease of 150 basis points QoQ from 40.7% in Q4FY24.
  • Profit After Tax (PAT): Rs 313.5 million, reflecting a 19.6% YoY increase from Rs 262.0 million in Q1FY24 but a 6.3% decrease QoQ from Rs 334.5 million in Q4FY24.

Commenting on the performance Suprita Reddy, MD & CEO said, “I'm happy to announce another strong quarter, highlighted by a remarkable YoY revenue growth of 29.1%, with an impressive 19.6% achieved organically. This growth was primarily driven by increased footfall and test volume, with our wellness holding strong at 13.4%.

I am also happy to share that, our hub center at VIP Road, Kolkata has successfully completed its first year of operations, reaching breakeven within just three quarters. This is a significant milestone in our growth journey, and we are excited about the opportunities the Kolkata market offers.

Looking ahead, I am pleased to announce the commencement of operations at our new 10,000-squarefoot, state-of-the-art hub facility in Ongole on August 8th. This facility, equipped with advanced radiology equipment such as a 3T MRI and a 160-slice cardiac CT, will offer a comprehensive range of integrated diagnostic services to our customers across the Palanadu region.”

Result PDF

Healthcare Services company Vijaya Diagnostic Centre announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Financial Performance: reported a robust YoY revenue growth of 28.3%, with a total revenue from operations of Rs 1,552.1 million.
  • Profitability: The company observed a Profit after Tax (PAT) increase by 21.7% in Q4FY24, reaching Rs 334.5 million.
  • Operational Metrics: Vijaya Diagnostic Centre revealed operational highlights, showing a Total Tests increase of 24.1% in Q4FY24 compared to Q4FY23.

FY24 Financial Highlights:

  • Financial Performance: FY24 showed a substantial revenue increase of 19.3%, accumulating to a total of Rs 5,478.1 million in revenue from operations.
  • Profitability: The annual PAT shot up by 40.4% to Rs 1,188.3 million in FY24.

Commenting on the performance Suprita Reddy, MD & CEO said, “I'm happy to share that this quarter too maintained our strong business performance, showcasing exceptional year-over-year revenue growth of 28.3%, of which an impressive 18.5% was achieved organically. This quarter also marked a notable milestone with the wellness contributing 14% of the revenue.

After completing six months of productive business operations, our Tier II hub centre in Mahbubnagar has gained a lot of momentum and broken even in just two quarters, showing a high demand for quality diagnostics in the area, and enforcing Vijaya’s reputation as a trusted brand.

We have made significant strides toward integrating PH Pune with the parent company. With effect from April 1st, 2024, we have successfully moved all of PH's essential ERP and other IT systems to the parent company's applications. Furthermore, it gives me great pleasure to announce that we have co-branded PH as Vijaya PH.

By strategically expanding and directing our capabilities towards future opportunities, we are confident in our ability to consistently deliver lasting value to our stakeholders”

 

Result PDF

Healthcare Services company Vijaya Diagnostic Centre announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Revenue from Operations increased by 4.1% YoY to Rs 1,210 million, Non-Covid Revenues grew by 22.4% YoY
      • The Non-COVID growth was driven by both radiology and pathology segments, highlighting the strength of our integrated model.
      • During Q4FY23, the Non-COVID business comprised 99% of the total revenue share as against 85% of revenue share in Q4FY22
      • Wellness share in Q4FY23 was up at 13.4% as against 8.4% in Q4FY22
      • Revenue composition from the B2C segment stood at 94.8%
    • EBITDA stood at Rs 491 million. EBITDA margin for the quarter was 40.6% as against 41.2% in Q4FY22
    • PAT stood at Rs 275 million. translating into a PAT margin of 22.7%
  • FY23:
    • Revenue from Operations stood at Rs 4,592 million as against Rs 4,624 million in FY22, NonCovid Revenues grew by 14.7% YoY
      • Wellness share in FY23 was up at 12.1% as against 6.8% in FY22
      • Revenue composition from the B2C segment continued to stay strong at 95%
    • EBITDA stood at Rs 1,820 million. EBITDA margin for FY23 was 39.6%
    • PAT stood at Rs 846 million. translating into a PAT margin of 18.4% in FY23

Commenting on the performance Suprita Reddy, CEO said, "We are extremely delighted to announce that Q4 witnessed the stellar performance, with the achievement of the highest ever quarterly Non-COVID revenue growth of 22.4% year-on-year. This was characterised by strong performance in both radiology and pathology segments, reinforcing the strength of our integrated model.

We consistently maintained our expansion momentum this quarter, expanding by 2 new hubs, 1 spoke and 2 mini spokes, taking the total centre count to 121. A noteworthy achievement during the quarter was the successful inauguration of VDCL’s state-of-the-art facility in Tirupati, Andhra Pradesh. Despite it being a relatively new location, we are glad to share that the customer response and the acceptance of our brand have been phenomenal.

It is a thing of great joy and pride that our Rajahmundry and Punjagutta hubs have demonstrated consistent performance amidst immense competition in the diagnostic space and achieved an operating break-even within an extremely short span of just two to three quarters from the commencement of operations.

The recently implemented comprehensive LIMS has successfully stabilized and is being effortlessly used across all our centres. This marks the fulfilment of a crucial milestone, enabling us to streamline operations and enhance efficiency on a larger scale, across our vast network of centres.

Taking progressively steady strides towards patient convenience and a holistic patient experience, we have successfully built and launched a robust and easy-to-use mobile app that significantly enhances the overall patient experience. It is available for all test types, both in radiology and pathology alike, making it one-of-a-kind in the diagnostic space. This all-encompassing app is available for both iOS & Android. The company has also completed the successful roll-out of a fully functional e-commerce website.

Our informed strategy of digital transformation, market research-backed approach for new market expansion and concentration on the enhancement of our network of centres will ensure sustainable year-on-year growth. We aim to adopt the highest standards of quality and to deliver a holistic customer experience whilst employing the most advanced technology and we firmly believe that this will enable us to make the most of the ever-evolving opportunity for growth in the diagnostic space."

 

 

Result PDF

Healthcare services company Vijaya Diagnostic Centre announced Q3FY23 results:

  • Q3FY23:
    • Revenue from operations increased by 2.1% YoY to Rs. 1,131 million, non-covid revenues grew by 9.8% YoY
      • During Q3FY23, the non-covid business comprised 99% of the total revenue share as against 92% revenue share in Q3FY22
      • Wellness share in Q3FY23 was up at 12.9% as against 8.5% in Q3FY22
      • Revenue composition from B2C segment stood at 95%
    • EBITDA stood at Rs. 443 million. EBITDA margin for the quarter was 39.1%
      • Healthy non-covid revenue coupled with operating leverage assisted margin performance despite costs on account of new centres
    • PAT stood at Rs 164 million, translating into a PAT margin of 14.5%
  • 9MFY23:
    • Revenue from operations decreased by 2.3% YoY to Rs 3,382 million, non-covid revenues grew by 12.2% YoY
      • Wellness share in 9MFY23 was up at 11.7% as against 6.3% in 9MFY22
      • Revenue composition from B2C segment continued to stay strong at 95%
    • EBITDA stood at Rs 1,329 million. EBITDA margin was 39.3%
    • PAT stood at Rs 571 million, translating into a PAT margin of 16.9%

Commenting on the performance, Suprita Reddy, CEO, said, “We are pleased to report steady performance during a seasonally soft quarter for the industry. The volume trends that were slow in the months of October and November, saw a significant improvement in December and we hope to carry this momentum into the upcoming quarter.

Our ongoing efforts to expand the network through the addition of new hubs and spokes has been progressing well. During this quarter, we opened 5 centres, including a one-of-its-kind facility at Punjagutta. Our newly opened state-of-the-art facilities in Punjagutta and Rajahmundry have received an overwhelmingly positive response from our customers. Additionally, our efforts to improve digital operations are proceeding smoothly, and we anticipate that these initiatives will considerably improve operational efficiency and enhance the customer experience across all of our centres.

Looking ahead, the outlook for the diagnostics industry remains positive, with increasing demand for advanced medical services and a growing emphasis on preventive healthcare. We remain confident that our integrated diagnostics offerings, well-established brand and our robust B2C network will enable us to capitalize on the huge market opportunity."

Result PDF

Healthcare service Vijaya Diagnostic Centre announced Q2FY23 results:

  • Q2FY23 vs Q2FY22:
    • Revenue from operations increased 7.1% YoY to Rs 1,207 million; non-Covid revenues grew by 15.1% YoY
      • During Q2FY23, the company witnessed MoM improvement in businesses across all segments that assisted revenue performance and registered QoQ growth of 15.7%
      • Wellness share in Q2FY23 was up at 12.4%, as against 6.7% in Q2FY22
      • Revenue composition from the B2C segment stood at 95%
    • EBITDA stood at Rs 487 million. EBITDA margin for the quarter was 40.4%
    • PAT stood at Rs 233 million, translating into a PAT margin of 19.3%
  • H1FY23 vs H1FY22:
    • Revenue from operations decreased by 4.4% YoY to Rs 2,251 million; non-Covid revenues grew by 13.4% YoY
      • Wellness share in H1FY23 was up at 11.1% as against 5.3% in H1FY22
      • Revenue composition from the B2C segment continued to stay strong at 95%
    • EBITDA stood at Rs 886 million; EBITDA margin for the quarter was 39.4%
    • PAT stood at Rs 408 million, translating into a PAT margin of 18.1%

Suprita Reddy, CEO, said, “We have delivered an encouraging performance in Q2FY23 with our revenues increasing by 15.7% and EBITDA increasing 22.2% QoQ. Despite considerably expanding our centres, our teams have made dedicated efforts to drive efficiencies leading to industry-leading EBITDA margins of 40.4% during the quarter.
We recently operationalised one of our largest 16,000 sqft state-of-the-art Punjagutta centre in Hyderabad. Along with the commissioning of major hubs in the past few months, we have made healthy progress on expanding our mid- and small-sized spokes in our focused markets during the quarter. Furthermore, various steps to enhance the overall digitisation aspect in our operations are progressing well and we expect these digital initiatives to considerably enhance the overall operational efficiency at all our centres.
The key pillars of our business are integrated diagnostic services, substantial presence in high-margin B2C business, and strong brand salience. This coupled with our other inherent strengths should assist the company to deliver sustainable growth, going forward.”

Result PDF

Trending News

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

Published on 18-Dec-2025 09:03

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Published on 18-Dec-2025 09:01

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Published on 18-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status